In a gene expression survey ([Supplementary Fig. 1a](#SD2){ref-type="supplementary-material"}), we identified the basic leucine zipper (bZIP) transcription factor ATF-like[@R7] (*Batf*) to be highly expressed in T~H~1, T~H~2 and T~H~17 cells compared to naïve T cells and B cells. *Batf* and *Batf3* (refs [@R2], [@R3]) form heterodimers with Jun[@R6],[@R7] and are considered repressors of AP-1 activity[@R3],[@R5],[@R6],[@R8],[@R19]. To assess its role in T cell differentiation[@R20], we generated *Batf^−/−^* mice ([Supplementary Fig. 2a, b](#SD2){ref-type="supplementary-material"}). *Batf^−/−^* mice lacked detectable *Batf* protein, were fertile and appeared healthy. Batf protein was low in naïve T cells, increased in T~H~2 cells, induced by activation ([Supplementary Fig. 2](#SD2){ref-type="supplementary-material"}), present in the nucleus and cytoplasm, but upon activation showed increased nuclear translocation ([Fig. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 1b, c](#SD2){ref-type="supplementary-material"}). *Batf^−/−^* mice had normal thymus, spleen and lymph node development and CD4^+^ and CD8^+^ T cell development ([Supplementary Fig. 3](#SD2){ref-type="supplementary-material"}, [Supplementary Fig. 4a, b](#SD2){ref-type="supplementary-material"}). Although *Batf*-transgenic mice had altered NKT cell development[@R21], *Batf^−/−^* mice had normal development of NKT cells ([Supplementary Fig. 4c](#SD2){ref-type="supplementary-material"}), B cells ([Supplementary Fig. 4d, e](#SD2){ref-type="supplementary-material"}), conventional and plasmacytoid dendritic cells ([Supplementary Fig. 5a, b](#SD2){ref-type="supplementary-material"}).

*Batf^−/−^* T cells displayed normal T~H~1 and T~H~2 differentiation ([Supplementary Fig. 6a](#SD2){ref-type="supplementary-material"}). Under T~H~17 conditions, *Batf^−/−^* T cells, but not *Batf*^+/−^ T cells, showed a dramatic reduction in IL-17 production, but had normal levels of IL-2, IFN-γ and IL-10 ([Fig. 1b, c](#F1){ref-type="fig"}). *Batf^−/−^* DO11.10^+^ T cells showed loss of IL-17 even after several passages under T~H~17 conditions ([Supplementary Fig. 6b](#SD2){ref-type="supplementary-material"}). *Batf^−/−^* CD8^+^ T cells also failed to produce IL-17 ([Supplementary Fig. 6c](#SD2){ref-type="supplementary-material"}). We generated transgenic mice expressing FLAG-tagged *Batf* under the control of the CD2 promoter[@R22]. *Batf*-transgenic DO11.10^+^ CD4^+^ T cells and CD8^+^ T cells had increased IL-17 production under T~H~17 conditions compared to controls ([Supplementary Fig. 6d, e](#SD2){ref-type="supplementary-material"}). Lamina propria CD4^+^ T cells, which constitutively express IL-17 in wild type mice[@R11], failed to produce IL-17 in *Batf^−/−^* mice ([Supplementary Fig. 6f](#SD2){ref-type="supplementary-material"}).

T~H~17 cells are the major pathogenic population in experimental autoimmune encephalomyelitis[@R10] (EAE), although factors other than IL-17A and IL-17F can contribute to disease[@R23]. *Batf* ^+/+^ mice immunized with myelin oligodendrocyte glycoprotein peptide 35--55 (MOG~35--55~) ([Fig. 2](#F2){ref-type="fig"}) developed EAE, but *Batf^−/−^* mice were completely resistant ([Fig. 2a](#F2){ref-type="fig"}). At peak disease, CNS-infiltrating and splenic CD4^+^ T cells from *Batf* ^+/+^ mice produced abundant IL-17 and IFN-γ, while T cells from *Batf^−/−^* mice produced no IL-17 ([Fig. 2b](#F2){ref-type="fig"}, [Supplementary Fig. 7a](#SD2){ref-type="supplementary-material"}). Since IL-6-deficient mice are resistant to EAE due to a compensatory increase in Foxp3^+^ T regulatory (T~reg~) cells[@R14], we analyzed splenic *Batf^+/+^* and *Batf^−/−^* CD4^+^ T cells for Foxp3 expression before and after MOG~35--55~ immunization ([Supplementary Fig. 7b, c](#SD2){ref-type="supplementary-material"}). *Batf^−/−^* mice had lower basal numbers of splenic Foxp3^+^ T cells compared to *Batf^+/+^* mice, but showed no change in Foxp3^+^ expression after MOG~35--55~ immunization ([Supplementary Fig. 7b, c](#SD2){ref-type="supplementary-material"}), suggesting that their resistance to EAE is not due to an increase in T~reg~ cells. To determine whether the resistance to EAE in *Batf^−/−^* mice resulted from a defect within T cells or other immune cells, we injected naïve *Batf^+/+^* CD4^+^ T cells or PBS control buffer into mice before MOG~35--55~ immunization ([Fig. 2c](#F2){ref-type="fig"}). *Batf^−/−^* mice receiving PBS remained resistant to EAE, but *Batf^−/−^* mice receiving naïve *Batf^+/+^* CD4^+^ T cells developed severe EAE ([Fig. 2c](#F2){ref-type="fig"}, [Supplementary Table 1](#SD2){ref-type="supplementary-material"}) with CNS-infiltrating IL-17-producing CD4^+^ T cells ([Supplementary Fig. 7d](#SD2){ref-type="supplementary-material"}). Thus, *Batf^−/−^* mice have a T cell-intrinsic defect preventing EAE.

*Batf* could control T~H~17 development by regulating IL-6 or TGF-β signaling. IL-6 receptor expression and IL-6-induced STAT3 phosphorylation were normal in *Batf^−/−^* T cells ([Supplementary Fig. 8a and b](#SD2){ref-type="supplementary-material"}). TGF-β induced normal levels of Foxp3 in *Batf^−/−^* CD4^+^ T cells ([Supplementary Fig. 8d](#SD2){ref-type="supplementary-material"}). While *Batf^−/−^* T cells failed to fully downregulate Foxp3 in response to IL-6 (ref [@R12]), neutralization of IL-2 abrogated increased Foxp3 in *Batf^−/−^* T cells, without restoring IL-17 production ([Supplementary Fig. 8d, e](#SD2){ref-type="supplementary-material"}). Thus, *Batf^−/−^* T cells exhibit normal TGF-β signaling and proximal IL-6 signaling, implying *Batf* may regulate downstream target genes.

IL-21, an early target of IL-6 signaling in CD4^+^ T cells[@R17], is required for T~H~17 development[@R14]--[@R16]. IL-21 was reduced in *Batf^−/−^* CD4^+^ T cells activated under T~H~17 conditions ([Fig. 3a](#F3){ref-type="fig"}). Addition of IL-21 failed to rescue T~H~17 development in *Batf^−/−^* T cells ([Fig. 3b](#F3){ref-type="fig"}) but IL-21-induced STAT3 phosphorylation was intact ([Supplementary Fig. 8c](#SD2){ref-type="supplementary-material"}), suggesting that *Batf* regulates other factors besides IL-21 during T~H~17 differentiation.

We performed DNA microarrays and quantitative RT-PCR (qRT-PCR) of *Batf^+/+^* and *Batf^−/−^* T cells activated with combinations of IL-6 and/or TGF-β ([Fig. 3c, d](#F3){ref-type="fig"} and [Supplementary Fig. 9](#SD2){ref-type="supplementary-material"}). This analysis identified several genes known to regulate T~H~17 development as *Batf*-dependent ([Fig. 3c, d](#F3){ref-type="fig"}, [Supplementary Fig. 9c](#SD2){ref-type="supplementary-material"} and [Supplementary Table 2](#SD2){ref-type="supplementary-material"}), including RORγt[@R17], RORα[@R24], the aryl hydrocarbon receptor[@R25],[@R26], IL-22 (ref [@R18]) and IL-17. However, IRF-4 (ref [@R13]) and SOCS gene expression were unchanged in *Batf^−/−^* T cells ([Supplementary Fig. 9b](#SD2){ref-type="supplementary-material"} and [Supplementary Table 4](#SD2){ref-type="supplementary-material"}). Early induction of RORγt was normal in *Batf^−/−^* T cells but was not maintained at 62h after stimulation ([Supplementary Fig. 11a](#SD2){ref-type="supplementary-material"}). *Batf* appeared necessary for expression of a subset of IL-6-induced genes, but was not required for expression of TGF-β-induced genes ([Fig. 3c](#F3){ref-type="fig"}, [Supplementary Fig. 9a](#SD2){ref-type="supplementary-material"} and [Supplementary Table 2](#SD2){ref-type="supplementary-material"}, [Supplementary Table 3](#SD2){ref-type="supplementary-material"}). However, *Batf* did not globally affect IL-6-induced responses, since IL-6-induced liver acute phase responses appeared normal in *Batf^−/−^* mice ([Supplementary Fig. 10](#SD2){ref-type="supplementary-material"}).

Since RORγt acts directly on the IL-17 promoter[@R27],[@R28], we asked whether RORγt could rescue T~H~17 development in *Batf^−/−^* T cells. In *Batf^+/+^* T cells, retroviral RORγt expression induced 38% IL-17 production, compared to only 1.6% IL-17 production induced by control retrovirus ([Fig. 3e](#F3){ref-type="fig"} and [Supplementary Fig. 11c](#SD2){ref-type="supplementary-material"})[@R11],[@R13]. But in *Batf^−/−^* T cells, retroviral RORγt expression induced only 5.7% IL-17 production ([Fig. 3e](#F3){ref-type="fig"} and [Supplementary Fig. 11c](#SD2){ref-type="supplementary-material"}). Even under T~H~17-inducing conditions, retroviral RORγt expression did not fully restore IL-17 production in *Batf^−/−^* T cells ([Supplementary Fig. 11b, c](#SD2){ref-type="supplementary-material"}). Retroviral expression of both Batf and RORγt in *Batf^−/−^* T cells induced 26% IL-17 production, compared to only 5% with RORγt alone, and 14% with Batf alone ([Supplementary Fig. 11d](#SD2){ref-type="supplementary-material"}), suggesting potential synergy between RORγt and Batf, and a possible direct action of Batf in transcription of IL-17 and other T~H~17-specific genes.

We used a reverse-strand retroviral reporter[@R29] to examine IL-17 promoter activity in primary *Batf^+/+^* and *Batf^−/−^* T cells ([Fig. 4a](#F4){ref-type="fig"}). Three days after activation, *Batf^−/−^* CD4^+^ T cells showed considerably less reporter activity than *Batf^+/+^* T cells, suggesting the proximal IL-17 promoter is *Batf*-responsive ([Fig. 4a](#F4){ref-type="fig"}). Using chromatin immunoprecipitation (ChIP) analysis of several conserved regions within the *IL-17a/IL-17f* locus ([Supplementary Fig. 12a](#SD2){ref-type="supplementary-material"}), we found that Batf specifically bound to the +9.6kb and +28kb intergenic regions within 24h after activation ([Fig. 4b](#F4){ref-type="fig"}, [Supplementary Fig. 12b, c](#SD2){ref-type="supplementary-material"}). By day 5 after stimulation, Batf bound specifically to several intergenic regions and to the proximal *IL-17a* and *IL-17f* promoters ([Fig. 4b](#F4){ref-type="fig"}, [Supplementary Fig. 12b, c](#SD2){ref-type="supplementary-material"}), with distal elements showing more rapid and stronger binding than proximal elements.

We next examined Batf binding to a consensus AP-1 probe[@R6] by EMSA. This probe formed two complexes in *Batf^+/+^* T~H~17 cell extracts ([Fig. 4c](#F4){ref-type="fig"}) that were dependent on stimulation ([Supplementary Fig. 13a](#SD2){ref-type="supplementary-material"}). Only the upper complex formed in *Batf^−/−^* T~H~17 cells ([Fig. 4c](#F4){ref-type="fig"}). An anti-Batf antibody inhibited the lower complex. In CD2-N-FLAG-*Batf*-transgenic T~H~17 cell extracts, the lower complex was specifically supershifted by an anti-FLAG antibody ([Fig. 4c](#F4){ref-type="fig"}). Thus, only the lower complex binding the consensus AP-1 probe in T~H~17 cells contains Batf.

Several potential Batf binding sites were identified by EMSA in the IL-17, IL-21 and IL-22 proximal promoters, including the IL-17 promoter region (−188 to −210) that bound Batf in ChIP ([Fig. 4b](#F4){ref-type="fig"}, [Supplementary Fig. 13b--d](#SD2){ref-type="supplementary-material"}). Another Batf-binding IL-17 promoter region (−155 to −187) overlapped with a reported RORγt-binding element[@R27]. As an EMSA probe, this region forms two complexes in T~H~17 cells ([Fig. 4d](#F4){ref-type="fig"}), with the lower complex being selectively inhibited by anti-Batf antibody, absent in *Batf^−/−^* T~H~17 cells, and supershifted by an anti-FLAG antibody in *Batf*-transgenic T~H~17 extracts ([Fig. 4d](#F4){ref-type="fig"}). We confirmed Batf binding to the IL-21 and IL-22 promoters by ChIP analysis ([Supplementary Fig. 13e](#SD2){ref-type="supplementary-material"}). The program CONSENSUS[@R30] determined that the Batf-binding element in the IL-17, IL-21 and IL-22 promoters resembles canonical AP-1 elements at positions 1 through 3, with variation at remaining nucleotides ([Supplementary Fig. 13f](#SD2){ref-type="supplementary-material"}). CONSENSUS did not identify other transcription factor binding sites enriched near Batf binding elements. We determined the composition of the Batf-containing complex using supershift analysis ([Fig. 4e](#F4){ref-type="fig"}). The upper complex supershifted with pan-anti-Fos antibody, whereas the lower complex supershifted with a pan-anti-Jun and anti-Batf antibodies. Anti-JunB supershifted the majority of the lower complex, but antibodies to c-Jun, JunD, ATF1 or ATF3 did not. Thus, Batf forms heterodimers preferentially with JunB during T~H~17 differentiation.

Although *Batf* and *Batf3* were considered AP-1 inhibitors[@R3]--[@R8], we have shown that they are required for the development of specific immune lineages[@R2]. *Batf* is selectively required for T~H~17 development, but unlike *Irf4* (Ref [@R13]), is not required for T~H~2 development. Since *Batf* is also expressed in T~H~1 and T~H~2 cells, it likely cooperates with other T~H~17-specific factors to regulate target genes. Future work will determine whether the actions of *Batf* involve distinct DNA binding specificity or unique protein-protein interactions with T~H~17 specific factors.

Methods Summary {#S1}
===============

Mice {#S2}
----

*Batf^−/−^* mice were generated by homologous recombination, deleting exons 1 and 2 of the *Batf* gene on the pure 129SvEv genetic background. The neomycin resistance cassette was removed from the targeted *Batf* allele in ES cells before generation of mice.

T cell differentiation assays {#S3}
-----------------------------

Naïve CD4^+^CD62L^+^CD25^−^ T cells were isolated by cell sorting and activated with plate-bound anti-CD3 and soluble anti-CD28 antibodies. Cultures were supplemented with anti-IL-4 (11B11; hybridoma supernatant), IFN-γ (Peprotech; 0.1ng/ml) and IL-12 (Genetics Institute; 10U/ml) for T~H~1; anti-IFN-γ (H22; BioXcell; 10µg/ml), anti-IL-12 (Tosh; BioXcell; 10µg/ml) and IL-4 (Peprotech; 10ng/ml) for T~H~2; anti-IL-4, anti-IL-12, anti-IFN-γ, IL-6 (Peprotech 20ng/ml) and TGF-β (Peprotech; 0.5ng/ml) for T~H~17 differentiation. Unless otherwise indicated, three days after activation cells were restimulated with PMA/ionomycin for 4h for intracellular cytokine analysis by flow cytometry.

Intracellular Staining {#S4}
----------------------

For intracellular cytokine staining, cells were stained for surface markers followed by fixation with 2% formaldehyde for 15 minutes at room temperature. Cells were then washed once in 0.05% saponin and stained with anti-cytokine antibodies in 0.5% saponin. Anti-phospho-STAT3 antibody (BD Pharmingen) was used according to the manufacturer's recommendations. Briefly, cells were stained for surface markers followed by fixation with 90% methanol at −20°C overnight. Cells were then washed and stained for phospho-Stat3 in PBS containing 3% FCS. Foxp3 staining was performed according to the manufacturer's recommendations using Foxp3 staining buffers (eBioscience).

Induction of EAE {#S5}
----------------

Mice (7--10 weeks old) were immunized subcutaneously with 100µg MOG~35--55~ peptide (Sigma) emulsified in CFA (IFA supplemented with 500µg *Mycobacterium tuberculosis*). One and three days later mice were given 300ng Pertussis Toxin (List Biological Laboratories) intraperitonally (i.p.). Clinical scores were assessed as described in methods. For T cell transfer experiments mice were injected with either PBS or 10^7^ *Batf^+/+^* CD4^+^ T cells 4 days prior to MOG~35--55~ immunization[@R13].
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![Loss of IL-17 production in *Batf^−/−^* T cells\
**a**, DO11.10^+^CD4^+^ T cells from CD2-N-FLAG-*Batf* transgenic mice or littermates were cultured with OVA/APCs under T~H~2 conditions for 7 days, and stained with antibodies to CD4 and FLAG. **b**,*Batf^+/+^* and *Batf^−/−^* CD4^+^CD62L^+^CD25 T cells cultured under T~H~17 conditions were restimulated with PMA/ionomycin on days 7 (left panel) or 3 (middle and right panels) and stained for IL-17, IFN-γ, IL-2 and IL-10. **c**, IL-17 and IFN-γ expression in DO11.10^+^CD4^+^ T cells from *Batf^+/+^Batf* ^+/−^ and *Batf^−/−^* mice activated with OVA/APCs under T~H~17 conditions. Data are representative of at least 2 independent experiments.](nihms115630f1){#F1}

![*Batf^−/−^* mice are resistant to EAE\
**a**,*Batf^+/+^* (n=12) and *Batf^−/−^* (n=13) mice were immunized with MOG~33--35~ peptide. (Mean clinical EAE scores +/− s.e.m, representative of two independent experiments). **b**, 13 days after EAE induction, CNS-infiltrating lymphocytes were stimulated with PMA/ionomycin, gated on CD4^+^ cells and stained for intracellular IL-17 and IFNγ (Clinical scores are in parentheses, data are representative of 2--3 mice per group). **c**,*Batf^+/+^* and *Batf^−/−^* mice were injected with control PBS buffer (n=5) or 1×10^7^*Batf^+/+^* CD4^+^ T cells (n=6) four days prior to EAE induction. Mean clinical scores are shown.](nihms115630f2){#F2}

![Batf controls multiple T~H~17-associated genes\
**a**, IL-21 expression in *Batf^+/+^* or *Batf^−/−^* T cells cultured under T~H~17 conditions determined by qRT-PCR and ELISA. (mean + s.d. 3 mice). **b**, IL-17 and IFN-γ expression of CD4^+^CD62L^+^CD25^−^ T cells cultured in **a** in the presence or absence of IL-21. **c**, Microarray analysis of anti-CD3/CD28-activated T cells at 72h, presented as heat maps of genes 5-fold-induced in *Batf^+/+^* T cells under T~H~17 conditions. **d**, IL-17 and IL-22 expression in *Batf^+/+^* or *Batf^−/−^* CD4^+^ T cells activated under T~H~17 conditions for 3 days. **e**, Anti−CD3/CD28-activated *Batf^+/+^* or *Batf^−/−^* CD4^+^ T cells were left uninfected or infected with RORγt-GFP-RV or control-GFP-RV, and stained for IL-17.](nihms115630f3){#F3}

![Batf directly regulates IL-17 expression\
**a**,*Batf^+/+^* and *Batf^−/−^* CD4^+^ T cells cultured under T~H~17 conditions were infected with hCD4-pA-GFP-RV-IL-17p reporter virus. GFP expression after PMA/ionomycin restimulation is shown. **b**, *Batf^+/+^* and *Batf^−/−^* CD4^+^ T cells cultured under T~H~17 conditions for 5 days were subjected to ChIP analysis of the indicated regions using anti-Batf antibody (mean + s.d.). **c, d, f**, EMSA supershift analysis of T~H~17 whole cell extracts using a consensus AP-1 **(c, f)** or the IL-17~(−155\ to\ −\ 187)~ probe **(d)**. (*Batf^+/+^* (WT), *Batf^−/−^* (KO), CD2-N-FLAG-*Batf* transgenic (TG), IL-17~(−155\ to\ −\ 187)~ and RORE probes were used as competitors).](nihms115630f4){#F4}
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